Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: granulocyte-macrophage colony-stimulating factor - Bolder BioTechnology

Drug Profile

Research programme: granulocyte-macrophage colony-stimulating factor - Bolder BioTechnology

Alternative Names: BBT-007; GM-CSF - Bolder BioTechnology; PEG-GM-CSF - Bolder BioTechnology; PEG-granulocyte-macrophage colony stimulating factor - Bolder BioTechnology

Latest Information Update: 25 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bolder BioTechnology
  • Class Antidementias; Granulocyte-macrophage colony-stimulating factors; Polyethylene glycols; Radioprotectives
  • Mechanism of Action Immunomodulators; Neutrophil stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute radiation syndrome; Alzheimer's disease; Neutropenia

Most Recent Events

  • 18 Jul 2019 Bolder BioTechnology receives SBIR grant from National Institute of Allergy and Infectious Diseases for granulocyte-macrophage colony-stimulating factor development in Acute radiation syndrome
  • 04 Dec 2017 Granulocyte-macrophage colony stimulating factor is still in preclinical development for acute radiation syndrome and neutropenia in USA (Bolder Biotechnology pipeline, December 2017)
  • 04 Dec 2017 Preclinical trials in Alzheimer's disease in USA (Parenteral) before December 2017 (Bolder Biotech pipeline, December 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top